Vos T, Abajobir AA, Abate KH; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390:1211–59. https://doi.org/10.1016/S0140-6736(17)32154-2.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92. https://doi.org/10.1038/s41572-020-00224-3.

Article  PubMed  PubMed Central  Google Scholar 

Gormley M, Creaney G, Schasche A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dental J. 2022;233(9):780–6. https://doi.org/10.1038/s41415-022-5166-x.

Article  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.

Article  PubMed  Google Scholar 

Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48. https://doi.org/10.1001/jamaoncol.2016.5688.

Article  PubMed Central  Google Scholar 

Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235–42. https://doi.org/10.1200/JCO.2015.61.6995.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yete S, D’Souza W, Saranath D. High-risk human papillomavirus in oral cancer: clinical implications. Oncology. 2018;94:133–41. https://doi.org/10.1159/000485322.

Article  PubMed  Google Scholar 

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301. https://doi.org/10.1200/JCO.2011.36.4596.

Article  PubMed  PubMed Central  Google Scholar 

Shah A, Malik A, Garg A, Mair M, Nair S, Chaturvedi P. Oral sex and human papilloma virus-related head and neck squamous cell cancer: a review of the literature. Postgrad Med J. 2017;93:704–9. https://doi.org/10.1136/postgradmedj-2016-134603.

Article  PubMed  Google Scholar 

Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen C, Yang CS. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345:1877–82. https://doi.org/10.1056/nejm011610.

Article  CAS  PubMed  Google Scholar 

Sturgis EM, Pytynia KB. After the smoke clears: environmental and occupational risks for carcinoma of the upper aerodigestive tract. Cancer J. 2005;11:96–103. https://doi.org/10.1097/00130404-200503000-00002.

Article  PubMed  Google Scholar 

•• Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72. https://doi.org/10.1056/NEJMra171571. An expert’s opinion on the pathogenesis and treatment options regarding head and neck cancer.

Article  CAS  PubMed  Google Scholar 

Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–94. https://doi.org/10.1056/NEJM199301213280306.

Article  CAS  PubMed  Google Scholar 

Peyrade F, Cupissol D, Geoffrois L, Rolland F, Borel C, Ciais C, Faivre S, Guigay J. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol. 2013;49:482–91. https://doi.org/10.1016/j.oraloncology.2013.01.005.

Article  PubMed  Google Scholar 

Fasano M, Corte CMD, Liello RD, Viscardi G, Sparano F, Iacovino ML, Paragliola F, Piccolo A, Napolitano S, Martini G, Morgillo F, Cappabianca S, Ciardiello F. Immunotherapy for head and neck cancer: present and future. Crit Rev Oncol Hematol. 2022;174:103679. https://doi.org/10.1016/j.critrevonc.2022.103679.

Article  PubMed  Google Scholar 

• Pereiera D, Martins D, Mendes F. Immunotherapy in head and neck cancer: when, how and why? Biomedicines. 2022;10:2151. https://doi.org/10.3390/biomedicines10092151. A review article elaborating ον immunotherapy in R/MHNSCC.

Article  CAS  Google Scholar 

Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and neck cancer immunotherapy: molecular biological aspectsof preclinical and clinical research. Cancers. 2023;15:852. https://doi.org/10.3390/cancers150300852.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune checkpoint inhibitors therapy era. Semin Cancer Biol. 2021;73:356–76. https://doi.org/10.1016/j.semcancer.2021.05.008.

Article  CAS  PubMed  Google Scholar 

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;10:487–511.

Article  Google Scholar 

Carlson RD, Flickinger JC, Snook AE. Talkin’ Toxin’s From Coley’s to modern cancer immunotherapy. Toxins. 2020;12(4):241. https://doi.org/10.3390/toxins12040241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin family-CTLA-4. Nature. 1988;328:267–70.

Article  Google Scholar 

Lipson EJ, Drake CG. Ipilimimab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958–62. https://doi.org/10.1158/1078-0432.CCR-11-1595.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishida Y. PD-1: its discovery, involvement in cancer immunotherapy and beyond. Cells. 2020;9(6):1376. https://doi.org/10.3390/cells9061376.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153–9. https://doi.org/10.1038/s41416-018-0131-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase ii study. J Clin Oncol. 2017;35:1542–9. https://doi.org/10.1200/JCO.2016.70.1524.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. KEYNOTE-048 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;393:156–67. https://doi.org/10.1016/S0140-6736(18)31999-8.

Article  CAS  PubMed  Google Scholar 

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184. https://doi.org/10.1186/s40425-019-0662-5.

Article  PubMed  PubMed Central  Google Scholar 

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–52. https://doi.org/10.1016/j.ejca.2018.11.015.

Article  CAS  PubMed  Google Scholar 

Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fasso M, O’Hear C, Powderly J. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29:2247–53. https://doi.org/10.1093/annonc/mdy411.

Article  CAS  PubMed  Google Scholar 

Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, Gordon MS, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Schöffski P, Grote HJ, Zhou D, Bajars M, Penel N. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN solid tumor trial. J Immunother Cancer. 2021;9:e002998. https://doi.org/10.1136/jitc-2021-002998.

Article  PubMed  PubMed Central  Google Scholar 

Chen SW, Li SH, Shi DB, Jiang WM, Song M, Yang AK, Li YD, Bei JX, Chen WK, Zhang Q. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int J Biol Markers. 2019;34(4):398–405. https://doi.org/10.1177/1724600819884722.

Article  CAS  PubMed  Google Scholar 

•• Ruffin AT, Li H, Vujanovic A, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumor microenvironment. Nat Rev Cancer. 2023;23(3):173–88. https://doi.org/10.1038/s41568-022-00531-9. An up to date manuscript on the significance of